ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO502

Stanniocalcin-1 Inhibits ER Stress and Renal Fibrosis via an AMP-Activated Protein Kinase-Dependent Pathway in HK2 Cells

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 308 CKD: Mechanisms of Tubulointerstitial Fibrosis

Authors

  • Yang, Eun mi, Chonnam National University Hospital, Gwangju, Korea (the Republic of)
  • Bae, Eun Hui, Chonnam National University Hospital, Gwangju, Korea (the Republic of)
  • Ma, Seong Kwon, Chonnam National University Hospital, Gwangju, Korea (the Republic of)
  • Kim, Soo Wan, Chonnam National University Hospital, Gwangju, Korea (the Republic of)
Background

The role of endoplasmic reticulum (ER) stress in the development of renal disease is a relatively recently described, and has been suggested as a cause for the fibrotic remodeling. Therefore, modulation of ER stress could be one of the possible therapeutic approaches to renal fibrosis. Stanniocalcin-1 (STC-1) is a multifunctional glycoprotein with antioxidant and anti-inflammatory properties and regulates AMP-activated protein kinase (AMPK) activity in the kidney. Activation of AMPK may reduce ER stress. The present study aimed to investigate the effects of STC-1 in ER stress and renal fibrosis in human renal proximal tubular (HK-2) cells

Methods

HK2 cells pretreated with STC-1 (200 ng/ml) for 1 hours followed by treatment with TGF-β (10 ng/ml) for 16 hours. To determine whether effect of STC-1 mediated by AMPK activation, pharmacological inhibitor (compound C, 5 uM) pretreated with STC-1. The protein expression of ER stress markers and fibrosis markers was determined by semiquantitative immunoblotting. The level of reactive oxygen species (ROS) was determined by fluorescent microscopy immunofluorescence.

Results

TGF-β treatment induced upregulation of glucose-related protein (GRP)78 and C/EBP homologous protein (CHOP) and STC-1 pretreatment attenuated the rise in the GRP 79 and CHOP. TGF-β treatment also induced upregulation of fibronectin and alpha-smooth muscle actin (α-SMA) and STC-1 pretreatment attenuated the TGF-β induced upregulation of fibronectin and α-SMA. STC-1 pretreatment significantly blocked TGF-β induced downregulation of AMPK and decreased level of ROS via upregulate the uncoupling protein (UCP2). On the other hand, compound C pretreatment with STC-1 before TGF-β treatment abolished the activation of AMPK, diminished the upregulation of UCP2, and aggravated ER stress and fibrosis but did not affect STC-1 expression.

Conclusion

STC-1 Inhibits ER stress and renal fibrosis via an AMPK Pathway and STC-1 may be a therapeutic target through reducing ER stress and renal fibrosis.

Funding

  • Government Support - Non-U.S.